Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / American Depositary Shares, each representing 6 Ordinary Shares
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
124,428,941
-
Share change
-
-27,345,949
-
Total reported value
-
$67,025,039
-
Put/Call ratio
-
48%
-
Price per share
-
$0.54
-
Number of holders
-
79
-
Value change
-
-$30,501,887
-
Number of buys
-
27
-
Number of sells
-
35
Institutional Holders of ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) as of Q4 2024
As of 31 Dec 2024,
ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) was held by
79 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
124,428,941 shares.
The largest 10 holders included
EcoR1 Capital, LLC, Long Focus Capital Management, LLC, NEA Management Company, LLC, Two Seas Capital LP, BAILLIE GIFFORD & CO, MPM ASSET MANAGEMENT LLC, MPM BIOIMPACT LLC, PFM Health Sciences, LP, BANK OF AMERICA CORP /DE/, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
79
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.